Technical analysis of Imunon, Inc. (IMNN): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications.
Price Performance
| 1 month | -10.76% |
| 3 months | -22.53% |
| Year-to-date | -62.99% |
| 1 year | -72.02% |
| 3 years | -91.97% |
| 5 years | -99.41% |
52-Week Range
| 52-week High | $5.71 |
| 52-week Low | $1.38 |
| Avg Volume (90d) | 116K |
Technical Indicators
| SMA 50 | $1.64 |
| SMA 200 | $2.66 |
| Beta | 2.12 |
| 30-day Volatility (annualised) | 38.0% |
| Price vs SMA 50 | -14.0% |
| Price vs SMA 200 | -47.0% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $4.55 | |
| 2025-11 | $4.12 | -9.5% |
| 2025-12 | $3.81 | -7.5% |
| 2026-01 | $3.32 | -12.9% |
| 2026-02 | $3.25 | -2.1% |
| 2026-03 | $2.94 | -9.5% |
| 2026-04 | $2.83 | -3.7% |
| 2026-05 | $2.18 | -23.0% |
| 2026-06 | $1.78 | -18.3% |
| 2026-07 | $1.59 | -10.7% |
| 2026-08 | $1.63 | +2.5% |
| 2026-09 | $1.41 | -13.5% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $1.41 |
| Market Cap | $6M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.77 |
| EV / EBITDA | -0.54 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 1.87 |
| Current Ratio | 1.82 |